Fitxers

712753.pdf (1001.43 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2011-06-11

Llicència de publicació

cc by nc nd (c) Formiga Pérez, Francesc et al, 2011
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178415

Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/14737167.2021.1933948

Resum

Objective: to estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) perspective. Methods: a costs and effects analysis were performed (probabilistic Markov model) with time horizons between 1 and 15 years, comparing the correct diagnosis of ATTR-CM versus the non-diagnosis. Transition probabilities were obtained from the ATTR-ACT study (placebo arm) and from the literature. Costs and healthcare resources were obtained from Spanish sources ( 2019) and from a panel of Spanish clinical experts. Results: after 1, 5, 10 and 15 years, the diagnosis of ATTR-CM would generate a gain of 0.031 (95%CI 0.025; 0.038); 0.387 (95%CI 0.329; 0.435); 0.754 (95%CI 0.678; 0.781) and 0.944 (95%CI 0.905; 0.983) life years per patient, respectively, with savings of 212 (95%CI -632; 633), 2,289 (95%CI 2,250; 2,517), 2,859 (95%CI 2,584; 3,149) and 2,906 (95%CI 2,669; 3,450) per patient, respectively, versus the non-diagnosis. Conclusions: just by correctly diagnosing ATTR-CM, years of life would be gained, cardiovascular hospitalizations would be avoided, and savings would be generated for the NHS, compared to the non-diagnosis of the disease.

Matèries

Amiloïdosi, Diagnòstic, Espanya

Matèries (anglès)

Amyloidosis, Diagnosis, Spain

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

FORMIGA PÉREZ, Francesc, et al. Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research. 2011. Vol. 11, num. 1-7. ISSN 1473-7167. [consulted: 24 of May of 2026]. Available at: https://hdl.handle.net/2445/178415

Exportar metadades

JSON - METS

Compartir registre